Overview

Analysis of Cytokines in Response to Treatment of Diabetic Macular Edema With 0.3mg Lucentis

Status:
Completed
Trial end date:
2018-02-02
Target enrollment:
Participant gender:
Summary
The protocol will measure a number of cytokines in addition to vascular endothelial growth factor in response to 0.3mg Lucentis.
Phase:
Phase 4
Details
Lead Sponsor:
Louis C. Glazer, MD
Vitreo-Retinal Associates, Michigan
Collaborators:
Genentech, Inc.
Michigan State University
Treatments:
Ranibizumab